Clinical Trials Logo
  1. Home
  2. Exercise Intervention
  3. NCT02533947

Cognition in Allogeneic Stem Cell Transplanted Patients and Sports — CaSpo  

Allogeneic Stem Cell Transplantation Clinical Trial

Official title:
Effects of Physical Exercise on Cognitive Functions in Patients After Allogeneic Stem Cell Transplantation

Clinical Trial Summary

Studies suggest that patients with hematological malignancies undergoing allogeneic hematopoietic stem cell transplantation (HSCT) are at risk for cognitive decline and long-term cognitive dysfunction. To address this issue, a randomized controlled intervention trial on the effect of physical exercise on cognition is conducted. In addition, the impact on psychological and physical health outcomes is evaluated. Results may benefit patients who suffer from disease- or treatment-associated cognitive change.

Clinical Trial Description

Studies suggest that patients with hematological malignancies undergoing allogeneic hematopoietic stem cell transplantation (HSCT) are at risk for cognitive decline and long-term cognitive dysfunction. To address this issue, a randomized controlled intervention trial on the effect of physical exercise on cognition is conducted. In addition, the impact on psychological and physical health outcomes such as depression, fatigue, health-related quality of life and physical fitness is evaluated. A healthy control group matched to the patients on age, gender, and education will be included to both control for practice effects on neuropsychological measures and allow additional comparisons on self-report measures. The healthy control group will undergo neuropsychological testing and questionnaire survey at baseline and 4 months. Demographic data will be collected from all study participants at baseline. Medical data will be collected from patients at all time points. Results may benefit patients who suffer from disease- or treatment-associated cognitive change. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02533947
Study type Interventional
Source Universitätsklinikum Hamburg-Eppendorf
Contact Angela Scherwath, Dr. phil.
Phone +49(40) 7410- 57565
Email a.scherwath@uke.de
Status Recruiting
Phase N/A
Start date June 2014
Completion date August 2019
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05443854 - Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01) Phase 3
Not yet recruiting NCT01212796 - Allo After Allo Stem Cell Transplantation Following Relapse After Allogeneic Transplant in Haematological Malignancies: Retrospective Results of the GETH N/A
Terminated NCT01185223 - Study Comparing Valganciclovir Versus Ganciclovir in Patients Following Allogeneic Stem Cell Transplantation Phase 3
Terminated NCT00737113 - Recombinant Human Growth Hormone (RH-GH) For Accelerating Immune Reconstitution Post Unrelated Cord Blood Transplant Phase 1
Recruiting NCT06028828 - Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation Phase 2
Not yet recruiting NCT03964922 - Immunoevasive Tactics Employed by Myeloid Malignancy After Allogeneic Stem Cell Transplantation N/A
Completed NCT03467074 - Role of Interferon-λ and Vaccine Response
Completed NCT02273024 - Exercise Prior to Allogeneic Hematologic Stem Cell Transplantation N/A
Recruiting NCT06093334 - Imaging of Chemotherapy-induced Morphological and Functional Lung Changes in Childhood ALL and HD N/A
Recruiting NCT03286530 - Ruxolitinib + Allogeneic Stem Cell Transplantation in AML Phase 2
Completed NCT01092026 - Unrelated Umbilical Cord Blood Transplantation With Coinfusion of Mesenchymal Stem Cells N/A
Recruiting NCT01160952 - Long-term Versus Short-term Sequential Therapy (Intravenous Itraconazole Followed by Oral Solution) of Itraconazole as Primary Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplantation Phase 2
Recruiting NCT00883714 - Exercise During the Allogeneic Stem Cell Transplantation Phase 3
Completed NCT04628338 - IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation Early Phase 1
Completed NCT06256341 - HHV-6-specific T-cell Reconstitution Among Children and Adolescents After Allogeneic Stem.
Completed NCT05088941 - Impact of COVID-19 Pandemic on Allogeneic Stem Cell Transplantation Organization : a French Experience
Not yet recruiting NCT06453460 - Prospect Eval of Efficacy of CMV-TCIP Direct Letermovir Prophylax After Allogen Hemato Cell Transpla Phase 2
Completed NCT01560689 - Inhaled BUDESONIDE/FORMOTEROL in Bronchiolitis Obliterans Following Stem Cell Transplantation Phase 2
Not yet recruiting NCT06297629 - A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation Phase 2
Completed NCT01929980 - Bortezomib to Treat Significant Complication of HSCT Phase 2